Annual Report

Overview

The report describes a year of commercial expansion for the company, with annual revenue increasing 47% to $0.99 million. It launched Xativa medicinal cannabis wafers in Australia, commenced Entity nutraceutical sales in China, and out-licensed Wafesil for the China market. COVID-19 disrupted travel and delayed the planned wafer-production capacity upgrade to 1Q 2021.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2020
Period: Ends 30 June 2020
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services